Are peptides legal in UAE and Dubai?
What current public UAE medicine and customs rules cover, why research-use labelling is not authorization, and where the official record does not support a blanket answer.
Update History ▾
August 2, 2026: Removed an unverified safe-harbour claim and all transactional guidance; narrowed the page to current official UAE medicine and import sources.
July 10, 2026: Replaced a retired MoHAP import-permit route with the current official permit document.
May 28, 2026: Added the US-side April 15–16, 2026 §503A Category 2 removal and the July 23–24 PCAC review for context.
May 18, 2026: Added May 2026 research update on FDA §503B compounding proposal (Federal Register 91 FR 23431); flagged UAE supply-chain implications.
May 9, 2026: Expanded the Dubai-specific medicine and import discussion.
April 13, 2026: Added an audit note on labelling, analytical evidence, and public UAE source limits.
April 11, 2026: Dubai-specific legal and customs brief created from current public UAE sources.
Initial draft
Short answer: the public UAE sources reviewed do not support a blanket statement that all peptides are legal or that an RUO label creates a safe harbour. The answer depends on the exact compound, intended use, product presentation, import route, medicines law and any controlled-substance schedule.
UAE government guidance clearly regulates medicines, controlled medicines and some personal-use medicine imports.[1][2][3] No public official text was located that creates a general exemption for peptide material labelled “For Research Use Only.” RUO wording is a statement of claimed intent, not authorization.
What do official UAE sources establish?
- Medicines and controlled medicines are regulated categories. The UAE government describes registration, prescription and permit controls for medicines.[1]
- Some personal-use medicine imports require prior permission. MoHAP publishes a permit process and supporting-document requirements.[3]
- Customs classification matters. Medicines, drugs and medical equipment are among categories requiring approval from the competent authority before import or export.[2]
- There is no public peptide-wide answer. The official pages do not publish a universal list saying every research-labelled peptide is approved, prohibited or exempt.
For broader jurisdictional context, see the global peptide-regulation guide.
Four questions that must remain separate
On phone, swipe sideways to compare all columns.
| Question | What answers it | What does not answer it |
|---|---|---|
| Is it an approved medicine? | Current UAE registration and authorization records | An RUO label or overseas trial status |
| Is it controlled? | The current schedule for the exact compound | The fact that other peptides are unscheduled |
| May it be imported? | Classification, route, purpose and the competent authority | A generic website statement |
| What does testing show? | A batch-linked analytical report and its stated method | Legal approval or import permission |
Why RUO labelling is not a legal conclusion
“For Research Use Only” can describe a claimed laboratory intent, but the label does not override how a product is presented, what claims are made, whether it is a medicine or controlled substance, or which import rules apply. Therapeutic claims, patient-directed instructions and medicine-style presentation can change the regulatory analysis.
The same separation applies to analytical documentation. A Certificate of Analysis can report identity, purity or another result for a tested sample. It cannot prove medicine approval, lawful import, lawful possession or a general UAE exemption. The COA library is therefore an evidence archive, not a regulatory authorization directory.
Retatrutide: trial status is not approval
Retatrutide remains an investigational Eli Lilly compound and is not an FDA- or UAE-approved medicine. A clinical-trial record shows research activity; it does not create a prescription, pharmacy, import or human-use pathway. Current evidence and filing plans are tracked in the retatrutide approval-status reference and the UAE trial-context guide.
- Do not infer a peptide-wide legal answer from one compound or one label.
- RUO wording is not a substitute for registration, import permission or schedule review.
- Medicine approval, controlled status, import status and analytical evidence are separate questions.
- For a real case, verify current primary sources and obtain qualified UAE advice.
FDA PCAC votes July 23–24, 2026: six peptides recommended
The FDA Pharmacy Compounding Advisory Committee concluded its July 23–24, 2026 meeting by voting to recommend six of the seven candidate peptides for the 503A Bulks List, in free base and acetate forms where applicable: BPC-157 (8–6, one abstention; evaluated use: ulcerative colitis), KPV (8–6, one abstention; wound healing and inflammatory conditions), TB-500 (8–6, one abstention; wound healing), MOTS-c (7–5, two abstentions; obesity and osteoporosis), Epitalon (insomnia), and Semax (8–5, one abstention; cerebral ischemia, migraine, trigeminal neuralgia). Emideltide (DSIP) was the only candidate not recommended (6–7, one abstention).
The recommendations are advisory, and FDA’s own scientific review staff opposed inclusion of all seven peptides, so the agency may still depart from the committee. Formal notice-and-comment rulemaking — which commonly takes a year or more — must conclude before any 503A list change takes effect. No compound gained an approved indication, and the votes do not change the research-only status of any research-grade peptide. Sources: FDA meeting page and materials; McDermott Will & Schulte meeting analysis. Full tallies and rulemaking outlook: PCAC explainer.
Our Research Standards
This article is built from current public UAE sources on drugs, controlled medicines, customs restrictions, and personal-use medicine imports. Where the public sources are explicit, we say so; where they do not establish a peptide-wide answer, we preserve that limitation. Read our editorial policy →
- The Official Portal of the UAE Government. Drugs and controlled medicines. Updated April 30, 2026. u.ae.
- The Official Portal of the UAE Government. Customs clearance and restricted goods. u.ae.
- Ministry of Health and Prevention. Issue of permit to import medicines for personal use. mohap.gov.ae.
- UAE Legislation. Federal Law by Decree No. 30 of 2021 on Combating Narcotics and Psychotropic Substances. uaelegislation.gov.ae.
- Tatmeen. National track-and-trace platform for healthcare supply chains in the UAE. tatmeen.ae.
- U.S. Food & Drug Administration. Proposal to exclude semaglutide, tirzepatide, and liraglutide from the §503B bulk drug substances list. Federal Register 91 FR 23431. April 30 / May 1, 2026. fda.gov
- Reuters. FDA removes 12 peptides from the §503A Category 2 Do-Not-Compound list. April 15, 2026. reuters.com
- Federal Register. Pharmacy Compounding Advisory Committee; Notice of Meeting (July 23–24, 2026). Notice 2026-07361, April 16, 2026. federalregister.gov